Skip to content
Products & Services · Total Revenues

Gross product sales — Total Revenues

Bristol-Myers Squibb Gross product sales — Total Revenues decreased by 28.1% to $16.93B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 14.8%, from $19.87B to $16.93B. Over 4 years (FY 2021 to FY 2025), Gross product sales — Total Revenues shows an upward trend with a 6.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2020
Last reportedQ1 2026Apr 30, 2026
Rolls up toTotal Revenue

How to read this metric

An increase indicates strong market demand and successful commercialization of the drug portfolio, while a decrease may signal competitive pressure, loss of patent exclusivity, or declining market share. Monitoring the gap between gross sales and net revenue helps identify trends in pricing pressure and payer negotiations.

Detailed definition

This metric represents the total gross revenue generated from the sale of pharmaceutical products before accounting for...

Peer comparison

Most large-cap pharmaceutical companies report gross-to-net adjustments, making this a standard starting point for evaluating top-line performance across the industry.

Metric ID: bmy_segment_gross_product_sales_total_revenues

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$16.97B$16.97B$16.97B$16.65B$17.3B$17.61B$18.08B$17.29B$18.11B$18.65B$19.63B$19.3B$20.78B$21.22B$22.37B$19.87B$22.18B$22.49B$23.54B$16.93B
QoQ Change+0.0%+0.0%-1.9%+3.9%+1.8%+2.7%-4.4%+4.8%+3.0%+5.3%-1.7%+7.7%+2.1%+5.4%-11.2%+11.6%+1.4%+4.6%-28.1%
YoY Change+1.9%+3.7%+6.5%+3.8%+4.7%+5.9%+8.6%+11.6%+14.7%+13.8%+14.0%+3.0%+6.7%+6.0%+5.2%-14.8%
Range$16.65B$23.54B
CAGR-0.1%
Avg YoY Growth+6.0%
Median YoY Growth+6.0%

Frequently Asked Questions

What is Bristol-Myers Squibb's gross product sales — total revenues?
Bristol-Myers Squibb (BMY) reported gross product sales — total revenues of $16.93B in Q1 2026.
How has Bristol-Myers Squibb's gross product sales — total revenues changed year-over-year?
Bristol-Myers Squibb's gross product sales — total revenues decreased by 14.8% year-over-year, from $19.87B to $16.93B.
What is the long-term trend for Bristol-Myers Squibb's gross product sales — total revenues?
Over 4 years (2021 to 2025), Bristol-Myers Squibb's gross product sales — total revenues has grown at a 6.7% compound annual growth rate (CAGR), from $67.9B to $88.09B.
What does gross product sales — total revenues mean?
The total revenue generated from product sales before subtracting rebates, discounts, and other pricing adjustments.